Aclaris Therapeutics, Inc. (ACRS) income statement
ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30147% above fair value
$3.50+0.12 (+3.55%)
Close on Nov 18, 2026Market cap $515.20MP/E –Yield –
Aclaris Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 79.5%
- Operating margin
- -1050.2%
- Net margin
- -921.5%
- Return on equity, FY2025
- -50.2%
Financial strength
- Current ratio
- 3.46
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 67.9%
Valuation
- P/E ratio
- –
- Price to sales
- 62.68
- Price to book
- 4.14
- Dividend yield
- –
See a number that looks wrong?